The Global Parkinson’s Genetics Programme (GP2) has announced the discovery of a genetic variant that increases the risk of Parkinson’s Disease (PD) in people of African and African admixed populations.
GP2 researchers identified the variant on the GBA1 gene as part of efforts to galvanise international and collaborative research into the genetics of Parkinson’s Disease and revolutionise treatment for the African and African admixed populations.
The GP2 researchers include the Nigeria Parkinson Disease Research (NPDR) network, the International Parkinson’s Disease Genomics Consortium (IPDGC)-Africa, University College London, the National Institutes of Health (NIH) in the United States, and 23andMe.
